ADAP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADAP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Non Operating Income is income or expense that comes from miscellaneous sources. Adaptimmune Therapeutics's Non Operating Income for the three months ended in Sep. 2024 was $-3.1 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.0 Mil.
The historical data trend for Adaptimmune Therapeutics's Non Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptimmune Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Non Operating Income | Get a 7-Day Free Trial | 0.08 | 1.16 | 3.85 | -2.83 | 19.54 |
Adaptimmune Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Non Operating Income | Get a 7-Day Free Trial | -0.43 | -0.31 | -0.06 | 0.50 | -3.09 |
Non Operating Income is income or expense that comes from miscellaneous sources.
Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cintia Piccina | officer: Chief Commercial Officer | 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R |
Elliot Norry | officer: Chief Medical Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Bertrand William C Jr | officer: Chief Operating Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
John Lunger | officer: Chief Patient Supply Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Adrian Rawcliffe | officer: Chief Financial Officer | 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146 |
Kristen Hege | director | 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070 |
Garry E Menzel | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Priti Hegde | director | TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142 |
Andrew R Allen | director | 2525 28TH STREET, SUITE 200, BOULDER CO 80301 |
Gavin Wood | officer: Chief Financial Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Joanna Elizabeth Brewer | officer: Chief Scientific Officer | 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Helena Katrina Tayton-martin | officer: Chief Operating Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
David M Mott | director | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Lawrence M Alleva | director | 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
James Noble | director, officer: Chief Executive Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 08-13-2024
By GuruFocus Research • 08-13-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-13-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.